Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Operating Expenses (2016 - 2025)

Regenxbio has reported Operating Expenses over the past 12 years, most recently at $308.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $308.3 million for Q4 2025, up 324.83% from a year ago — trailing twelve months through Dec 2025 was $475.0 million (up 98.98% YoY), and the annual figure for FY2025 was $331.6 million, up 4.73%.
  • Operating Expenses for Q4 2025 was $308.3 million at Regenxbio, up from $82.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for RGNX hit a ceiling of $308.3 million in Q4 2025 and a floor of -$276.5 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $85.2 million (2021), compared with a mean of $69.8 million.
  • Biggest five-year swings in Operating Expenses: tumbled 410.26% in 2023 and later soared 4912.06% in 2025.
  • Regenxbio's Operating Expenses stood at $85.1 million in 2021, then increased by 4.77% to $89.1 million in 2022, then tumbled by 410.26% to -$276.5 million in 2023, then soared by 126.25% to $72.6 million in 2024, then skyrocketed by 324.83% to $308.3 million in 2025.
  • The last three reported values for Operating Expenses were $308.3 million (Q4 2025), $82.1 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.